Back to Directory Rashmi Mehta Email rashmi.s.mehta@gsk.com Phone 919-272-7593 Institution GSK Request an Update Affiliated Studies IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Closed to Accrual
IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Closed to Accrual
